Linked Life Data

2091687

Source:http://linkedlifedata.com/resource/pubmed/id/2091687

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1991-6-13
pubmed:abstractText
In a European multicenter trial the weekly rates of increase in hematocrit and reticulocyte values were investigated in hemodialyzed patients with transfusion-dependent anemia treated with recombinant human erythropoietin (rHuEPO). Within a few months of therapy, the number of transfusion-dependent patients decreased to less than 5% of the group. Patients with aluminum overload indicated by elevated basal serum levels or elevated levels after a desferrioxamine challenge showed a significantly reduced response to rHuEPO. whereas in patients with elevated levels of parathyroid hormone a normal response to rHuEPO was found.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0253-5068
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
279-84
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism.
pubmed:affiliation
II Medical Clinic, St. Markus Hospital, Frankfurt, FRG.
pubmed:publicationType
Journal Article, Clinical Trial, Multicenter Study